Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP recommends approval of Esbriet for IPF

Dec. 21, 2010

Genentech provides update on Avastin for metastatic breast cancer

Dec. 20, 2010

EMA recommends approval of Xiapex for treatment of Dupuytren's contracture

Dec. 20, 2010

Novartis withdraws application to extend Zometa indication in E.U.

Dec. 17, 2010

E.C. approves sunitinib malate for treatment of pancreatic neuroendocrine tumors

Dec. 17, 2010

Alexza provides regulatory update for Staccato Loxapine

Dec. 10, 2010

European approval of Brilique for prevention of atherothrombotic events

Dec. 10, 2010

UCB updates progress from third quarter of 2010

Dec. 1, 2010

FDA clears design of phase III oritavancin trials SOLO-1 and -2

Dec. 1, 2010

New Juvista formulation for children significantly improves scar appearance

Nov. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....